المؤلفون: Moran, D, Bilotti, E, Rome, S, Richards, T, Faiman, BM, Colson, K, Westphal, J, Tariman, J, Spong, JE, Miller, K, Miceli, T, McCullagh, E, Mangan, PA, Love, G, Lilleby, K, Jenkins, BS, Doss, D, Daily, K, Bertolotti, P

المصدر: Clinical Lymphoma and Myeloma; September 2009, Vol. 9 Issue: 6 pS6-S7, 2p

المؤلفون: Chakraborty R; Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY., Rybicki L; Taussig Cancer Center, Cleveland Clinic, Cleveland, OH., Wei W; Taussig Cancer Center, Cleveland Clinic, Cleveland, OH., Valent J; Taussig Cancer Center, Cleveland Clinic, Cleveland, OH., Faiman BM; Taussig Cancer Center, Cleveland Clinic, Cleveland, OH., Samaras CJ; Taussig Cancer Center, Cleveland Clinic, Cleveland, OH., Anwer F; Taussig Cancer Center, Cleveland Clinic, Cleveland, OH., Khorana AA; Taussig Cancer Center, Cleveland Clinic, Cleveland, OH.

المصدر: Blood [Blood] 2022 Dec 08; Vol. 140 (23), pp. 2443-2450.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Venous Thromboembolism*/etiology , Venous Thromboembolism*/genetics, Humans ; Cytogenetics

المؤلفون: Chakraborty R; Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA., Rybicki L; Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Valent J; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Garcia AVM; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Faiman BM; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Khouri J; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Samaras CJ; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Anwer F; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Khorana AA; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. khorana@ccf.org.

المصدر: Blood cancer journal [Blood Cancer J] 2021 Jun 25; Vol. 11 (6), pp. 121. Date of Electronic Publication: 2021 Jun 25.

نوع المنشور: Letter

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Multiple Myeloma*/drug therapy , Multiple Myeloma*/mortality , Thromboembolism*/chemically induced , Thromboembolism*/mortality , Thromboembolism*/prevention & control, Aspirin/*administration & dosage , Heparin, Low-Molecular-Weight/*administration & dosage , Warfarin/*administration & dosage, Adult ; Aged ; Aged, 80 and over ; Bortezomib/administration & dosage ; Bortezomib/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Disease-Free Survival ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Retrospective Studies ; Survival Rate

المؤلفون: Khouri J; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH., Faiman BM; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH., Grabowski D; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Mahfouz RZ; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Department of Clinical Pathology, Menoufia University, Shebin-Elkom, Egypt., Khan SN; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Interdisciplinary Nanotechnology Centre, Aligarh Muslim University, Aligarh, India., Wei W; Taussig Cancer Institute, Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH., Valent J; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH., Dean R; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH., Samaras C; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH., Jha BK; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Lazarus H; Case Comprehensive Cancer Center, Cleveland, OH; Department of Hematology and Oncology, Seidman Cancer Center, University Hospitals, Cleveland, OH., Campagnaro EL; Case Comprehensive Cancer Center, Cleveland, OH; Department of Hematology and Oncology, Seidman Cancer Center, University Hospitals, Cleveland, OH; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI., Malek E; Case Comprehensive Cancer Center, Cleveland, OH; Department of Hematology and Oncology, Seidman Cancer Center, University Hospitals, Cleveland, OH., Reed J; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Karam MA; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Hamilton K; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Fada S; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Kalaycio M; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH., Liu H; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Sobecks R; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH., Saunthararajah Y; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Chew Y; Zymo Research, Irvine CA., Orloff M; Lerner Research Institute, Genomic Core Facility, Cleveland Clinic, Cleveland, OH; Department of Epidemiology, University of Arkansas for Medical Sciences, Little Rock, AR; Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR., Reu FJ; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Morsani College of Medicine, University of South Florida, Tampa, FL. Electronic address: frederic.reu@moffitt.org.

المصدر: Seminars in hematology [Semin Hematol] 2021 Jan; Vol. 58 (1), pp. 45-55. Date of Electronic Publication: 2020 Dec 28.

نوع المنشور: Clinical Trial, Phase I; Journal Article

بيانات الدورية: Publisher: W.B. Saunders Country of Publication: United States NLM ID: 0404514 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-8686 (Electronic) Linking ISSN: 00371963 NLM ISO Abbreviation: Semin Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Multiple Myeloma*/genetics, Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Azacitidine/adverse effects ; DNA Methylation ; Dexamethasone/adverse effects ; Humans ; Lenalidomide/pharmacology ; Lenalidomide/therapeutic use ; Treatment Outcome

المؤلفون: Chakraborty R; Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Rybicki L; Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Nakashima MO; Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Dean RM; Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Faiman BM; Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Samaras CJ; Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Rosko N; Department of Pharmacy, Cleveland Clinic, Cleveland, OH, USA., Dysert H; Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Valent J; Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Anwer F; Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.

المصدر: British journal of haematology [Br J Haematol] 2020 Jun; Vol. 189 (6), pp. 1074-1082. Date of Electronic Publication: 2020 Feb 28.

نوع المنشور: Clinical Trial; Journal Article

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Immune System Diseases*/etiology , Immune System Diseases*/immunology , Immune System Diseases*/mortality , Immune System Diseases*/pathology , Multiple Myeloma*/immunology , Multiple Myeloma*/mortality , Multiple Myeloma*/therapy, Adult ; Aged ; Aged, 80 and over ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Survival Rate

المؤلفون: Chakraborty R; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Rybicki L; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Tomer J; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Samaras CJ; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Faiman BM; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Valent J; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Majhail NS; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

المصدر: Leukemia & lymphoma [Leuk Lymphoma] 2019 Dec; Vol. 60 (14), pp. 3544-3551. Date of Electronic Publication: 2019 Jul 05.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

مواضيع طبية MeSH: Global Health* , Patient Reported Outcome Measures* , Quality of Life*, Immunoglobulin Light-chain Amyloidosis/*therapy, Adult ; Aged ; Aged, 80 and over ; Female ; Follow-Up Studies ; Humans ; Immunoglobulin Light-chain Amyloidosis/epidemiology ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Surveys and Questionnaires ; Survival Rate ; United States/epidemiology

المؤلفون: Chakraborty R; Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Liu HD; Moffitt Cancer Center, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Tampa, FL., Rybicki L; Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Tomer J; Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Khouri J; Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Dean RM; Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Faiman BM; Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Kalaycio M; Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Samaras CJ; Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Majhail NS; Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Valent J; Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.

المصدر: American journal of hematology [Am J Hematol] 2019 Apr; Vol. 94 (4), pp. 439-445. Date of Electronic Publication: 2019 Feb 06.

نوع المنشور: Clinical Trial; Comparative Study; Journal Article

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Databases, Factual* , Multiple Myeloma*/diagnosis , Multiple Myeloma*/genetics , Multiple Myeloma*/mortality , Multiple Myeloma*/therapy, Adult ; Aged ; Aged, 80 and over ; Disease Progression ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Incidence ; Male ; Middle Aged ; Recurrence ; Survival Rate

المؤلفون: Khouri J; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Kin A; Division of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA., Thapa B; Department of Internal Medicine, Cleveland Clinic Fairview Hospital, Cleveland, OH, USA., Reu FJ; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Bumma N; Division of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA., Samaras CJ; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Liu HD; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Karam MA; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Reed J; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Mathur S; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Faiman BM; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Devries G; Division of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA., Zonder J; Division of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA., Valent J; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.

المصدر: British journal of haematology [Br J Haematol] 2019 Apr; Vol. 185 (2), pp. 342-344. Date of Electronic Publication: 2018 Jun 25.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal/*therapeutic use , Antineoplastic Agents/*therapeutic use , Immunoglobulin Light-chain Amyloidosis/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Drug Administration Schedule ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Recurrence ; Treatment Outcome

المؤلفون: Faiman BM; Hematology and Medical Oncology Department, Cleveland Clinic in Ohio, USA. faimanb@ccf.org, Mangan P, Spong J, Tariman JD

مؤلفون مشاركون: The International Myeloma Foundation Nurse Leadership Board

المصدر: Clinical journal of oncology nursing [Clin J Oncol Nurs] 2011 Aug; Vol. 15 Suppl, pp. 66-76.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Oncology Nursing Press Country of Publication: United States NLM ID: 9705336 Publication Model: Print Cited Medium: Internet ISSN: 1538-067X (Electronic) Linking ISSN: 10921095 NLM ISO Abbreviation: Clin J Oncol Nurs

مواضيع طبية MeSH: Leadership* , Societies, Nursing* , Survivors*, Kidney/*physiopathology , Multiple Myeloma/*physiopathology, Humans ; Multiple Myeloma/nursing

المؤلفون: Bilotti E; Multiple Myeloma Division of John Theurer Cancer Center, Hackensack University Medical Center, New Jersey, USA. ebilotti@humed.com, Faiman BM, Richards TA, Tariman JD, Miceli TS, Rome SI

مؤلفون مشاركون: International Myeloma Foundation Nurse Leadership Board

المصدر: Clinical journal of oncology nursing [Clin J Oncol Nurs] 2011 Aug; Vol. 15 Suppl, pp. 5-8.

نوع المنشور: Consensus Development Conference; Journal Article

بيانات الدورية: Publisher: Oncology Nursing Press Country of Publication: United States NLM ID: 9705336 Publication Model: Print Cited Medium: Internet ISSN: 1538-067X (Electronic) Linking ISSN: 10921095 NLM ISO Abbreviation: Clin J Oncol Nurs

مواضيع طبية MeSH: Leadership* , Practice Guidelines as Topic* , Survivors*, Multiple Myeloma/*nursing, Accidental Falls ; Female ; Humans ; Kidney/physiopathology ; Male ; Multiple Myeloma/physiopathology ; Needs Assessment ; Nurse's Role